Opendata, web and dolomites

ActiTOX SIGNED

Active organotypic models for nanoparticle toxicological screening

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "ActiTOX" data sheet

The following table provides information about the project.

Coordinator
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. 

Organization address
address: HANSASTRASSE 27C
city: MUNCHEN
postcode: 80686
website: www.fraunhofer.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙191˙400 €
 EC max contribution 1˙191˙400 € (100%)
 Programme 1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
 Code Call H2020-MSCA-RISE-2018
 Funding Scheme MSCA-RISE
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2023-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) coordinator 161˙000.00
2    INOCURE SRO CZ (PRAHA) participant 239˙200.00
3    SZECHENYI ISTVAN UNIVERSITY HU (GYOR) participant 193˙200.00
4    BIOFABICS LDA PT (PORTO) participant 133˙400.00
5    TECHNISCHE UNIVERSITAET WIEN AT (WIEN) participant 124˙200.00
6    OSPIN GMBH DE (BERLIN) participant 105˙800.00
7    USTAV EXPERIMENTALNI MEDICINY AKADEMIE VED CESKE REPUBLIKY VEREJNA VYZKUMNA INSTITUCE CZ (PRAHA 4) participant 105˙800.00
8    UNIVERSITAET GRAZ AT (GRAZ) participant 69˙000.00
9    ORTHOSERA GMBH AT (KREMS AN DER DONAU) participant 50˙600.00
10    BIONEER A/S DK (HOERSHOLM) participant 9˙200.00

Map

 Project objective

Nanoparticles and new drugs are undergoing complex toxicity evaluation prior to their use in products for customers. However, the traditional pre-clinical testing protocols are delivering significant disadvantages both from ethical (animal testing) and functional (high attrition rate in clinical testing) point of view. ActiTOX reacts to this problem by the development of a novel, pre-clinical, high content, in vitro testing platform focused on the evaluation of nanoparticles/drugs via ADME (absorption, distribution, metabolism, excretion) toxicity studies. In order to advance the current state of art the project will employ biomimetic scaffolds, drug delivery systems, human induced pluripotent stem cells (iPSCs), 3D-microfluidics and modular bioreactor technology. ActiTOX aims to increase the relevance of in vitro studies and provide a scalable approach for their use in drug development and toxicological screening. In order to achieve the project goals, a training network enabling efficient short-term secondments of ER and ESR between academia and industry will be established. The cooperation between stakeholders helps closing the gap between them and oint innovation to foster the current state of the art. ActiTOX will mediate it via networking, research, training, workshop, innovation and dissemination actions in form of short-term secondments. The project fulfils the aim of a RISE project and delivers significant social impact, increases knowledge based economy and creates long lasting cooperation strengthening the European research area.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ACTITOX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ACTITOX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.3.)

CONMECH (2019)

Nonsmooth Contact Dynamics

Read More  

VIDEC (2020)

Visualizing Death Inducing Protein Complexes

Read More  

DisTerrMem (2019)

Memory Across Borders: Dealing with the Legacy of Disputed Territories

Read More